Rufinamide: a new anti-epileptic medication

• HAUSER WA, RS, ANNEGERS JF, ANDERSON VE: Seizure recurrence after a first unprovoked seizure; an extended follow-up. Neurology (1990) 400:1163-1170.
   Google Scholar
• KWAN P, BRODIE MJ: Early identification of refractory epilepsy. N. Engl. J. Med. (2000) 342:314-319.
   PubMed Web of Science ®Google Scholar
• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ, LEVY RH, LOISEAU P, PERUCCA E: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. (1999) 34(1):1-41.
   PubMed Web of Science ®Google Scholar
• MCLEAN MJ, SCHMUTZ M, POZZA M: The influence of rufinamide on sodium currents and action potential firing in rodent neurons. Epilepsia (2005) 46:296.
   Google Scholar
• WHITE HS, SCHMUTZ M, POZZA M, WOLF H, STABLES J, KUPFERBERG H: The anticonvulsant profile and tolerability of rufinamide in mice and rats. Epilepsia (2005) 46(Suppl. 8):305-306.
   Google Scholar
• CHEUNG WK, KIANIFARD F, WONG A: Intra- and inter-subject variabilities of CGP 33101 after replicate single oral doses of two 200 mg tablets and 400 mg suspension. Pharm. Res. (1995) 12(12):1878-1882.
   PubMed Web of Science ®Google Scholar
• CARDOT JM, LECAILLON JB, CZENDLIK C, GODBILLON J: The influence of food on the disposition of the antiepileptic rufinamide in healthy volunteers. Biopharm. Drug Dispos. (1998) 19(4):259-262.
   PubMed Web of Science ®Google Scholar
• ELGER C, STEFAN H, PERDOMO C: Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures. Epilepsia (2005) 46(Suppl. 8):83-84 (Abstract No. 1.201).
   Google Scholar
• ARROYO S et al.: Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures. Epilepsia (2005) 46(Suppl. 8):193-193.
   PubMedGoogle Scholar
• CRITCHLEY D et al.: Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia (2005) 46:209-209.
   Google Scholar
• BRUNNER LA, HARRIQAN EP, JOHN VA, POWELL ML: Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400 – 1200 mg. Am. J. Ther. (1994) 1(3):215-220.
   PubMedGoogle Scholar
• WALDMEIER F et al.: Metabolism of the new anticonvulsant trial drug rufinamide (CGP 33101) in healthy male volunteers: 6.60. American Epilepsy Proceedings. Epilepsia (1996) 37(Suppl. 5):167 (Abstract).
   Google Scholar
• CHANG SW, CHOI L, KAROLCHYK MA: A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia (1998) 39(Suppl. 6):59.
   Google Scholar
• SACHDEO R et al.: Pharmacokinetics and safety of adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia (1998) 39(Suppl. 6):166-167.
   Google Scholar
• FUSEAU E et al.: Population pharmacokinetic drug–drug interaction analyses of rufinamide studies in patients with epilepsy. Epilepsia (2005) 46:210-211.
   Google Scholar
• SVENDSEN KD, CHOID L, CHEN BL: Single-center, open-label, multiple dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia (1998) 39(Suppl. 6):59.
   Google Scholar
• PÅLHAGEN S, CANGER R, HENRIKSEN O, VAN PARYS JA, RIVIÈRE ME, KAROLCHYK MA: Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res. (2001) 43(2):115-124.
   PubMed Web of Science ®Google Scholar
• ELGER C et al.: Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures. Epilepsia (2006) 47:140-140.
   Google Scholar
• BRODIE MJ et al.: Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. Neurology (2006) 66(5):A35-A36.
   PubMedGoogle Scholar
• GLAUSER T et al.: Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients. Epilepsia (2005) 46(Suppl. 8):194-195.
   Google Scholar
• GLAUSER T et al.: Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial: LBS. 001. Neurology (2005) 64(10):1826-1826.
   Web of Science ®Google Scholar
• GLAUSER T et al.: Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome (1.356). Epilepsia (2005) 46(Suppl. 8):408-408.
   Google Scholar
• BITON V et al.: Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalized tonic-clonic seizures. Epilepsia (2005) 46(Suppl. 8):206-206.
   Google Scholar
• LESSER RP et al.: Efficacy and safety of rufinamide monotherapy for the treatment of patients with refractory partial seizures. Epilepsia (2005) 46:177-178.
   Google Scholar
• TODOROV A et al.: Efficacy and safety of high- versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures. Epilepsia (2005) 46(Suppl. 8):218-219.
   Google Scholar
• KRAUSS G, PERDOMO C, ARROYO S: Short-term and long-term safety of rufinamide in patients with epilepsy. Epilepsia (2006) 47:140-140.
   Google Scholar
• MARCHAND M, CRITCHLEY D et al.: The effect of rufinamide on the QT interval in healthy subjects treated during 18 days with multiple ascending doses: a population PKPD analysis. Proceedings of Annual Meeting of the Population Approach Group in Europe (2005).
   Google Scholar
• KRAUSS GL, PERDOMO CA, ARROYO S: Short and long-term safety of rufinamide in patients with epilepsy. Epilepsia (2005) 46(Suppl. 8):213-213.
   Google Scholar
• BRODIE MJ et al.: Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures. Epilepsia (2005) 46(Suppl. 8):171-171.
   PubMedGoogle Scholar
• ALDENKAMP AP, ALPHERTS WC: The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia (2006) 47(7):1153-1159.
   PubMed Web of Science ®Google Scholar
• CONRY JA: Pharmacological teatment of catastrophic eilepsies. Epilepsia (2004) 45(Suppl. 5):12-16.
   PubMed Web of Science ®Google Scholar
• PÅLHAGEN S et al.: Efficacy and safety of rufinamide in patients with refractory epilepsy: I. 10. American Epilepsy Proceedings. Epilepsia (1997) 38(Suppl. 8):207-208.
   Google Scholar

Website

• http://www.emea.europa.eu/humandocs/PDFs/EPAR/inovelon/H-660-en6.pdf European Medicine Commission: European Public Assessment Report Inovelon: Scientific Discussion, in EPARs for authorised medicinal products for human use (2007).
   Google Scholar